Hematology

The approval follows the separate US approvals in December 2023 and January 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The director of the Adult Sickle Cell Clinic and associate professor at University of Alabama Birmingham pointed out access to a sickle cell specialist as one such priority.

Hemogenyx noted that the agency confirmed all issues pointed out in the initial clinical hold letter from June 2023 had been sufficiently addressed by the company.

The BAFFR-CAR T-cell therapy is being investigated in a phase 1 single-center and phase 1 multicenter trial in B-ALL and B-NHL.

The clinical assistant professor at Stanford Medicine discussed potential applications for machine learning in analyzing data in medicine.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The new Cell and Gene Therapy Access Model will be led by the Centers for Medicare & Medicaid Services’ Innovation Center.

The assistant professor at MD Anderson Cancer Center discussed a trial she is leading at MD Anderson with NK cells and cetuximab in colorectal cancer.

The professor in residence of pediatrics at University of California San Francisco discussed trends in research for SCD gene therapy.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive™ team.

For World Cancer Day, held annually on February 4, take a look at the stories that have stood out in oncology cell therapy so far this year.

Review top news and interview highlights from the week ending February 2, 2024.

The director of the Adult Sickle Cell Clinic and associate professor at University of Alabama Birmingham discussed work the National Alliance of Sickle Cell Centers is conducting.

Vor Bio recently also announced data from the phase 1/2 trial of trem-cel.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Kyverna has also announced data on its proprietary CAR-T manufacturing process, Ingenui-T.

The company also shared that it has manufactured sufficient IDP-023 to supply the Phase 1 clinical trial through the second half of 2024.

The clinical professor in the Department of Human Genetics at University of Texas Rio Grande Valley discussed how a personalized gene editing approach may help patients avoid development of FVIII inhibitors.

Sana also recently announced data from the first patient treated with its CD19-targeted CAR.

Review top news and interview highlights from the week ending January 26, 2024.

The European Medicines Agency Committee for Advanced Therapies will likewise hold a SAG-O meeting regarding the Type II variation application for the CAR-T in the EU.

The clinical assistant professor at Stanford Medicine also shared his excitement on the recent approvals of lovo-cel and exa-cel.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.